Dupixent Lawsuit Cancer Claims: What Patients Need to Know

What Is Dupixent And Who Uses It?

Dupixent (dupilumab) is a human monoclonal antibody that blocks the interleukin-4 receptor alpha and is used to treat several type 2 inflammatory diseases.

It is approved as a subcutaneous injection for adult and pediatric patients aged 6 months and older with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies.

Dupilumab treated patients also include asthma patients 6 years and older with eosinophilic or oral corticosteroid-dependent asthma who need add-on maintenance therapy.

Beyond patients with atopic dermatitis and asthma, dupilumab therapy is indicated for chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease with an eosinophilic phenotype.

Many patients are prescribed dupilumab after years of inadequate control on topical steroids, systemic immunosuppressants, or other therapies and are seeking more stable, long-term symptom relief.

For severe atopic dermatitis in particular, Dupixent can reduce skin inflammation, itching, and flare frequency in adults and young children when managed by a specialist.

Dupixent is administered as an injection under the skin, usually every 2 to 4 weeks, with dosing tailored to the patient’s age, weight, and indication.

Because it targets shared immune pathways, dupilumab therapy is now used across dermatology, allergy, pulmonology, and ENT practices for a broad spectrum of chronic inflammatory conditions.

Patients who may be prescribed Dupixent include:

• Adults and children with moderate to severe atopic dermatitis that is not adequately controlled with topical prescription therapies
• Adults and pediatric patients with eosinophilic or oral corticosteroid-dependent asthma who require add-on maintenance therapy
• Adults with chronic rhinosinusitis with nasal polyps whose symptoms remain uncontrolled on standard treatments
• Adults and adolescents with eosinophilic esophagitis requiring targeted biologic therapy
• Adults with prurigo nodularis who have persistent, treatment-resistant nodular itch and rash
• Adults with chronic obstructive pulmonary disease with an eosinophilic phenotype who need add-on biologic therapy
• Adults and children 6 years and older with allergic fungal rhinosinusitis following sinus surgery and ongoing disease activity

These approved uses mean Dupixent users range from infants and young children with severe atopic dermatitis to older adults living with asthma or other allergic diseases.

In real-world settings, many patients with atopic dermatitis receiving dupilumab also have overlapping conditions such as asthma or nasal polyps, so dupilumab treated patients often span multiple specialties.

Understanding The Alleged Dupixent Cancer Risks

Medical evidence on alleged Dupixent cancer risks is mixed, and it comes from real-world data rather than a clear signal in the original phase 2 and 3 trials, where no lymphoma or cutaneous lymphoma cases were reported at approval.

Over time, case reports of dupilumab associated lymphoma have described patients who developed cutaneous T-cell lymphoma (CTCL) or other lymphoid cancers after starting Dupixent, often with skin lesions that initially looked like ordinary atopic dermatitis.

Recent database work, including TriNetX and insurance or health-system cohorts, has reported that some patients with atopic dermatitis receiving dupilumab appear to have a higher relative risk of developing cutaneous lymphoma, with at least one Dermatologic Therapy analysis estimating a several-fold increase in CTCL risk compared to non-users, particularly in older adults and often within about a year of starting therapy.

In contrast, a large TriNetX retrospective cohort study across atopic dermatitis and other type 2 inflammatory diseases found that the underlying conditions themselves carry elevated lymphoma risk, including CTCL and non-Hodgkin lymphoma, and that dupilumab use did not increase lymphoma rates compared to other systemic treatments and may modestly reduce risk in some non-dermatologic groups.

A separate population-based cohort in asthma compared nearly 15,000 patients who initiated dupilumab with more than 730,000 on combination therapy with inhaled corticosteroids and LABA and found that the primary outcome of new-onset lymphoma, especially T-cell and NK-cell lymphomas, was more frequent in the dupilumab group, while secondary outcomes included other malignancies and all-cause mortality.

In that study, dupilumab treatment was associated with higher lymphoma incidence but also significantly lower all-cause mortality, leading the authors to call for long-term surveillance and further research rather than immediate changes in use.

Pharmacovigilance reviews of the FDA’s FAERS database show CTCL is disproportionately reported with dupilumab compared to other cutaneous lymphomas and other malignant neoplasms, and in March 2025 the FDA formally identified CTCL as a potential serious risk and opened a safety review, though it has not concluded that Dupixent causes lymphoma or added a specific cancer warning to the label.

At the same time, narrative reviews and expert groups stress that CTCL often begins as subtle, eczema-like patches caused by abnormal T cells in the skin, so some “dupilumab associated lymphoma” cases may represent unrecognized cancer that was already present and only became obvious after inflammation changed under treatment.

Mechanistic and integrative epidemiology studies explore how IL-4/IL-13 blockade might interact with malignant T cells, but those models remain theoretical and do not yet prove causation.

Taken together, these data suggest a concerning but still unsettled signal: CTCL and related T-cell lymphomas appear more often than expected in certain dupilumab-treated populations, while overall malignancy and mortality patterns are more reassuring.

For patients and clinicians, the practical takeaway is not panic but vigilance, especially for new or changing skin lesions, patches, or tumors that do not behave like typical eczema, and for older adults with late-onset or atypical dermatitis who start Dupixent.

Cutaneous T-Cell Lymphoma (CTCL) And Other T-Cell Lymphomas

Cutaneous T-cell lymphoma (CTCL) is a rare cancer of abnormal T cells that primarily affects the skin, often beginning with red, itchy patches or plaques that can closely resemble chronic eczema.

In the context of dupilumab treatment, recent studies suggest that some adults treated for presumed atopic dermatitis later go on to develop CTCL or related T-cell lymphomas, sometimes within the first year of therapy.

Certain cohort and database studies have reported a higher risk of CTCL in dupilumab-treated eczema patients compared to similar patients who were not exposed to the drug, although researchers continue to debate whether this reflects a true drug effect, unmasking of pre-existing disease, or a mix of both.

At the same time, other malignancies do not appear consistently increased across all Dupixent users, which is why the current concern is focused on CTCL and related T-cell and NK-cell lymphomas rather than a broad, generalized cancer signal.

Key clinical and scientific points about CTCL and other T-cell lymphomas in Dupixent litigation include:

• CTCL often starts with skin-limited lesions that look like stubborn eczema, making early cancer difficult to recognize without targeted biopsies.
• Several case series describe patients whose presumed dermatitis worsened or changed under dupilumab treatment, only to be reclassified as CTCL after repeat biopsies.
• Observational data and registry studies report elevated rates of CTCL in dupilumab-treated atopic dermatitis cohorts when compared to non-dupilumab controls.
• T-cell and NK-cell lymphomas, rather than B-cell lymphomas or solid tumors, account for most of the reported lymphoid cancers in recent studies linking dupilumab and lymphoma risk.
• Expert reviews stress that these findings support a signal that warrants further research and close clinical monitoring, but they do not yet prove that Dupixent universally causes CTCL or other T-cell malignancies.

CTCL Symptoms That Can Look Like Severe Eczema

Cutaneous T-cell lymphoma (CTCL) can carry a potential risk of being mistaken for severe eczema because early lesions often look like the same red, itchy, scaly patches seen in chronic atopic dermatitis.

People with long-standing “eczema” or asthma receiving dupilumab who notice changes in their skin or new systemic symptoms may need closer evaluation, since some CTCL and even related natural killer (NK) cell lymphomas have first appeared in this setting.

CTCL can also cause whole-body symptoms, such as enlarged lymph nodes and unexplained weight loss, that are easy to overlook when attention is focused only on the skin.

Common CTCL symptoms that can look like severe eczema include:

• Red, itchy, scaly patches or plaques that persist for months or years despite standard eczema treatments
• Skin lesions that thicken, form raised plaques, or develop nodules or tumors over time
• Rashes or plaques on unusual or sun-protected areas of the body, especially if they spread or change in appearance
• Areas of skin that change color, become mottled, or develop persistent discoloration not typical of prior eczema flares
• Intense, unrelenting itch that feels different from a person’s usual eczema pattern
• Enlarged lymph nodes in the neck, armpits, or groin
• Unexplained weight loss, fevers, or night sweats along with worsening skin disease

Misdiagnosis, Delayed Diagnosis, And Disease Progression

Misdiagnosis is common in cutaneous T-cell lymphoma because early lesions resemble stubborn eczema, so many patients spend years cycling through topical steroids, systemic drugs, and even dupilumab without anyone suspecting cancer.

When CTCL is treated as routine dermatitis instead of a malignancy of abnormal T cells, biopsies may be delayed, interpreted as nonspecific inflammation, or never repeated after the initial result.

This kind of delayed diagnosis allows disease to progress from flat patches to thicker plaques and tumors, and in some cases to involve lymph nodes, blood, and internal organs.

In patients on Dupixent, persistent or changing skin disease is sometimes attributed to “refractory eczema” or a partial drug response instead of prompting a new workup, which can add months of lost time.

By the time CTCL or another T-cell lymphoma is recognized, people may require more aggressive treatment, including multi-agent chemotherapy, radiation, or advanced systemic therapies.

From a legal perspective, this sequence of misdiagnosis, delayed diagnosis, and disease progression is central to allegations that inadequate warnings and limited clinical guidance left patients and doctors unprepared to consider lymphoma in the setting of ongoing skin symptoms.

For families weighing a Dupixent cancer claim, reconstructing this timeline through dermatology notes, pathology reports, and imaging is critical to understanding how long CTCL was present before it was finally identified.

Do You Qualify For A Dupixent Cancer Lawsuit?

Whether you qualify for a Dupixent cancer lawsuit will depend on your medical history, your diagnosis, and how closely your lymphoma timeline tracks your Dupixent use.

Current lawsuits claim that Dupixent may cause, accelerate, or mask cutaneous T-cell lymphoma (CTCL), a cancer that is often misdiagnosed as severe eczema for years before it is recognized.

As of early 2026, Dupixent (dupilumab) lawsuits are still in the early stages, with the first wrongful death lawsuit filed in October 2025 by a family whose relative died from T-cell lymphoma months after starting the drug.

These cases allege that manufacturers Sanofi and Regeneron failed to warn about risks connecting Dupixent to CTCL and that better warnings could have prompted earlier biopsies and cancer detection.

A motion has been filed to consolidate federal Dupixent lymphoma cases into Multidistrict Litigation (MDL) in the Northern District of Georgia as of February 2026, but individual eligibility is still assessed case by case.

Factors that lawyers may consider when evaluating whether you qualify for a Dupixent cancer lawsuit include:

• A confirmed diagnosis of CTCL, other T-cell lymphoma, or related lymphoid cancer after using Dupixent
• Medical records showing that your skin disease was treated as “eczema” or atopic dermatitis for months or years before lymphoma was recognized
• Documentation of when Dupixent was prescribed, how long you remained on the drug, and how your skin or systemic symptoms changed over time
• Evidence that CTCL or another lymphoma was diagnosed within a relatively short period after starting Dupixent, particularly in an adult with new or atypical dermatitis
• Oncology, dermatology, or pathology reports that suggest delayed diagnosis or disease progression during Dupixent treatment
• Any history of persistent or worsening skin lesions, plaques, or tumors that were repeatedly labeled as dermatitis without timely repeat biopsy
• Records relating to a death from T-cell lymphoma or CTCL in someone who used Dupixent, which may support a potential Dupixent wrongful death claim

Dupixent users who develop unusual or worsening skin symptoms should speak with their doctors promptly, both for potential early detection of CTCL and to document the sequence of events in their medical records.

If you or a family member fit several of these criteria, a lawyer familiar with Dupixent cancer litigation can review your records and advise whether pursuing a lawsuit is appropriate in your situation.

Evidence in a Dupixent Lawsuit

Evidence in a Dupixent lawsuit focuses on objective documentation that connects a person’s Dupixent use, their skin and systemic symptoms, and the eventual lymphoma diagnosis.

Lawyers look for records that show how long a person was treated for “eczema” or another inflammatory condition, what changed after starting Dupixent, and when CTCL or another lymphoma was first suspected or confirmed.

The strength of a case often depends on whether the records support a clear timeline: prescription of Dupixent, evolving or worsening symptoms, delayed diagnosis, and documented cancer progression.

Expert witnesses then use this medical evidence to assess whether Dupixent may have contributed to a delayed diagnosis, accelerated disease, or additional harm.

Examples of evidence in a Dupixent lawsuit may include:

• Dermatology and allergy records showing the original diagnosis (such as atopic dermatitis) and the decision to prescribe Dupixent
• Pharmacy records documenting when Dupixent was first filled, dosing, and how long treatment continued
• Pathology reports and biopsy results confirming CTCL or another T-cell or NK-cell lymphoma
• Clinical notes describing persistent, changing, or treatment-resistant skin lesions that were managed as eczema before lymphoma was recognized
• Imaging studies (CT, PET, MRI) used to stage the lymphoma and track progression or response to treatment
• Hospital and oncology records detailing cancer treatments such as chemotherapy, radiation, or immunotherapy and their outcomes
• Bloodwork and lab results that help show disease severity or spread over time
• Correspondence or visit summaries in which doctors discuss ongoing symptoms, possible misdiagnosis, or the decision to continue Dupixent despite worsening disease
• Death certificates, autopsy reports, and hospice records in cases involving a Dupixent-related wrongful death claim
• Employment, disability, and insurance records that document how the cancer affected work, income, and daily functioning

Potential Compensation In A Dupixent Lymphoma Case

Damages in a Dupixent lymphoma case are the financial and non-financial losses tied to the diagnosis, treatment, and long-term impact of CTCL or another lymphoma on a person and their family.

Lawyers assess damages by reviewing medical records, billing statements, employment and income history, and how the cancer has affected daily life, independence, and long-term health.

They also consider future needs, including ongoing medical care, reduced earning capacity, and the psychological and relational impact of living with or losing someone to lymphoma.

In settlement discussions or at trial, these documented losses are used to support a claim for compensation tailored to the specific harms in that individual case.

Potential compensation in a Dupixent lymphoma case may include:

• Past medical expenses for diagnosis, hospitalizations, biopsies, and cancer treatment
• Future medical costs, including ongoing oncology care, monitoring, medications, and supportive therapies
• Out-of-pocket expenses such as travel to specialists, lodging, and caregiving support
• Lost wages from time away from work during treatment, recovery, or disability
• Loss of future earning capacity when cancer or its treatment limits a person’s ability to work long term
• Costs of home health care, rehabilitation, or long-term assistance with daily activities
• Pain and suffering for physical pain, intense itching, invasive procedures, and treatment side effects
• Emotional distress and loss of enjoyment of life tied to a cancer diagnosis and its consequences
• Loss of consortium or loss of companionship for spouses and close family members
• Funeral and burial expenses, along with other wrongful death damages, in cases where lymphoma leads to death

TorHoerman Law: Reviewing Dupixent Cancer Lawsuit Claims

TorHoerman Law is closely following the evolving science and litigation surrounding Dupixent and lymphoma, including CTCL and other T-cell cancers.

Dupixent lawsuits allege that Sanofi and Regeneron failed to adequately warn patients and prescribing doctors about the potential risk that serious skin cancers could be masked, accelerated, or diagnosed only after years of treatment for what was believed to be severe eczema or another inflammatory disease.

Our team reviews medical records, pathology reports, and treatment timelines to evaluate whether a particular cancer diagnosis may fit within these emerging claims and whether a lawsuit is appropriate for an individual client.

If you or a loved one were prescribed Dupixent and later diagnosed with cutaneous T-cell lymphoma or another lymphoma, you can contact TorHoerman Law to discuss your situation.

We offer free, no-obligation case evaluations and can review your medical history, treatment records, and diagnosis to help you understand your potential legal options.

Reach out to TorHoerman Law today to speak with our team about a possible Dupixent cancer lawsuit claim.